What is Addex Therapeutics?
Addex Therapeutics operates as a specialized clinical-stage pharmaceutical entity dedicated to the research and commercialization of allosteric modulators. These orally available small molecule drugs represent a sophisticated approach to treating neurological disorders, including post-stroke recovery, substance use disorder, and chronic cough. By targeting specific receptor sites, the company aims to provide more precise therapeutic interventions than traditional orthosteric ligands. The organization maintains a robust collaborative model, working alongside global partners to navigate the rigorous clinical development process and address the unmet needs of healthcare providers and patients worldwide.
How much funding has Addex Therapeutics raised?
Addex Therapeutics has raised a total of $87M across 2 funding rounds:
Series B
$55M
Series C
$32M
Series B (2004): $55M with participation from Index Ventures and Sofinnova Partners
Series C (2021): $32M led by Sofinnova Partners, Roche Venture Fund, SR One, Index Ventures, and TVM Capital
Key Investors in Addex Therapeutics
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm acts as a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics. They provide hands-on strategic and operational support to translate innovative technologies into new medicines.
Index Ventures
Index Ventures is a global venture firm investing in the next generation of entrepreneurs from seed to IPO. They partner with founders who challenge the status quo to build enduring companies across various high-growth sectors.
What's next for Addex Therapeutics?
With the support of its latest capital injection, Addex Therapeutics is well-positioned to accelerate its clinical development programs. The strategic focus will likely remain on advancing its lead candidates through critical trial phases while maintaining its collaborative research framework. As the company matures, the emphasis will shift toward demonstrating the efficacy of its allosteric modulation platform in human trials, a milestone that will be pivotal for future commercial viability and potential licensing agreements. Investors will be closely monitoring the company's ability to translate its scientific innovation into tangible clinical outcomes, which remains the primary driver of value in the high-stakes biotech industry.
See full Addex Therapeutics company page
